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The respiratory tract is in constant contact with inhaled antigens from the external 
environment. In order to shape its line of defense, it is populated by various types of 
immune cells. Taking into account the scientific breakthroughs of nanomedicine and 
nanoparticle drug delivery, we can think of the respiratory tract as an ideal target 
organ to study and develop nanocarrier-based vaccines to treat respiratory tract 
disorders. Nanoparticles have been proven capable of specific cell targeting and, 
when suitably engineered, are able to induce an immunomodulatory effect. The aim 
of this review is to highlight in vitro approaches to the study of nanoparticle-lung 
immune cell interactions and recent advances in the targeting of immune cells using 
nanoparticle-based systems.
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The rapid expansion of nanotechnology has 
resulted in the production of an impressive 
variety of nanoparticles (NPs) that have been 
defined by the European Network on the 
Health and Environmental Impact of Nano-
materials, according to ISO guidelines (ISO 
TC 229/TS 27687:2008), as objects with all 
three spatial dimensions on the nanoscale 
(1–100 nm). Due to their small size they pos-
sess high surface-to-volume ratios compared 
with bulk materials of the same chemical 
composition and their unique physicochemi-
cal properties allow implementation of NPs 
in a variety of biomedical applications, for 
instance as diagnostic or therapeutic agents, 
and in novel vaccine formulations [1,2]. Even 
though NPs intended for biomedical appli-
cations are part of the high risk, high pay-
off global nanotechnology phenomenon, the 
process of converting basic nanomedicine 
research into commercially viable products 
is likely to be long and difficult. Acceptance 
and integration of the products of nanotech-
nology, particularly in nanomedicine, will 
be a challenge for a number of reasons. Not 
only approval by the regulatory agencies is 
required but also manufacturing processes 
require significant technological and cultural 
adjustments on the part of the producers [3].
Potential biomedical application of NPs 
can occur by means of the lungs via inhala-
tion, the gastrointestinal tract via digestion, 
the skin via direct application or the blood 
vessels via intravenous administration [4–6]. 
Although most of the recent developments 
in the field of biomedical NPs has considered 
intravenous injection as the major adminis-
tration path, simultaneously, the lungs are 
considered a promising pathway for deliver-
ing NPs as biomedical therapeutic or diag-
nostic agents via inhalation [7] due to their 
vast epithelial surface area of >150 m2 and an 
extremely thin air–blood barrier of less than 
1 μm [7,8]. The respiratory tract is function-
ally subdivided into a conducting region con-
sisting of the airways (trachea, bronchi and 
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bronchioles), and the actual respiratory part where 
gas exchange occurs (alveoli) [9] (Figure 1). Following 
inhalation, airborne particles deposit in the different 
regions of the respiratory tract in a size-dependent 
manner [10,11]. Larger particles (1–10 μm) preferen-
tially deposit in trachea and bronchi, whereas smaller 
particles (i.e., NPs) tend to deposit in the peripheral 
lung regions (alveoli). Therefore, depending on the size 
of the particles, different compartments of the respira-
tory tract may be targeted. Once deposited, particles 
interact with pulmonary surfactants and are displaced 
by wetting forces into the aqueous hypophase [12,13], 
where the interaction with pulmonary cells occurs. 
Then, particles can be cleared either via phagocytosis 
by macrophages or via mucociliary clearance within the 
conducting airways or translocation through the air–
blood tissue barrier in the more peripheral regions [14]. 
The latter might result in NPs entering systemic cir-
culation [15,16] and distribution of particles to multiple 
organs [17]. Depending on the particle properties and 
the rate of clearance, interaction with lung cells may 
cause cytokine-induced inflammation [18].
To maintain its homeostasis and thus to protect the 
lungs and subsequently the whole organism from invad-
ing pathogens, the lung is home to a variety of immune 
cell populations, such as phagocytic cells and antigen 
presenting cells, that is, macrophages and dendritic 
cells (DCs) [19,20]. The primary role of immature DCs, 
strategically positioned within the mucosal tissue, is to 
sample antigen by extending protrusions into the air-
way or alveolar lumen [21]. In this process, depending 
on the nature of the antigen, DCs may get activated 
via pattern recognition receptors and enter matura-
tion process [22]. In case of activation/maturation DCs 
rapidly migrate to the draining lymph nodes [21–23]. 
In the course of maturation antigens are processed by 
the DCs and presented to naive T cells via the major 
histocompatibility complex (MHC II) in combina-
tion with upregulated co-stimulatory molecules on the 
DCs surface (CD40, CD80, CD86) and the release of 
cytokines. The type and combination of the cytokines 
released will determine the nature of effector T cells 
induced (Th1, Th2, Treg and Th17) [22] (Figure 2).
Therefore, specific targeting of lung-resident cells by 
NPs has been of great interest over the past decade [24]. 
It has been reported that adequately engineered NPs 
can specifically target cell populations in the differ-
ent compartments, that is, conducting area (or lung 
parenchyma) of the respiratory tract [25], or via recep-
tor-mediated mechanisms; the latter being the most 
common mechanisms for this purpose [26]. When NPs 
encounter cells, they can trigger immunomodulatory 
effects [25,26]. The latter effect is desirable in the case 
of NP-based drug carriers/vaccines where NPs may 
serve as adjuvants (as reviewed elsewhere [26–29]). On 
the other hand, NPs might also be accidentally intro-
duced into therapeutics, thus significantly contribut-
ing to therapeutic efficiency [30]. Nevertheless, NP 
immunogenicity as well as antigenicity (i.e., the abil-
ity to induce immune response, and the ability to be 
specifically recognized by the antibodies, respectively) 
has recently been reviewed in detail by Ilinskaya and 
Dobrovolskaia [31], concluding that by tuning the 
physicochemical properties of NP-based carriers it is 
possible to either stimulate the immune system or to 
avoid its recognition. On the other hand, from the bio-
technological perspective, improving our understand-
ing of the undesirable immunogenicity and antigenic-
ity of nanoparticulate-contaminated therapeutics is an 
essential future step required for the safe design of the 
nanomedicine products [31]. Moreover, the adverse side 
effects of NPs encountering immune cells also need to 
be considered, such as immune-mediated destruction 
or rejection, which can result in the elimination of NPs 
and/or immunotoxicity, and thus possible damage to 
the immune system and pathological states: a phenom-
enon that has been reviewed in the past [32]. Herein 
we discuss the basic functions of the lung-resident 
immune cells, such as macrophages and DCs, but also 
consider cells which can be activated by down-stream 
reactions in the draining lymph nodes, such as B or 
T cells as well as the in vitro approaches used in the 
fields of NP-based drug delivery, immune-modulation 
and specific cell targeting.
The aim of the review is to show the state-of-the-
art of the in vitro human lung immune cell-model 
systems, applicable for a first evaluation of biomedi-
cal NPs aimed to be used for therapeutic and diag-
nostic purposes as well as to provide an overview of 
the current knowledge of specifically designed NPs 
intended for modulation of different lung diseases. 
The interactions between NPs and various compo-
nents of the immune system have become an active 
area of research in nanotechnology (recently reviewed 
in Dobrovolskaia et al. [30]). However, there is a lack of 
systematic reviews available on the routes of adminis-
tration of biomedical NPs in human lungs, and their 
bio compatibility with pulmonary immune cells per se. 
The majority of the literature data on NP-based pul-
monary treatments has been derived from mouse (or 
other mammal) studies, but there is currently incom-
plete data on the interaction between NPs and the 
human pulmonary immune system. However, for a 
better appraisal of the subject, we have occasionally 
incorporated findings and interpretations arising from 
studies on other mammalian objects. Finally, taking 
together the anatomy and physiology of the respiratory 
tract, the unique functions of the different lung cell 
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Figure 1. Schematic presentation of the structural organisation of the human respiratory immune system. The 
upper respiratory epithelium, lining the inner surface of the trachea, bronchi and bronchioles, is composed of 
a pseudostratified layer of ciliated cells, mucus-producing cells and secretory cells, and is responsible for the 
elimination of potential pathogens and foreign particles with the action of the mucociliary escalator. The distal 
regions of the lung epithelium, the alveolar septa, represent the site of the gas exchange. In both regions, 
macrophages are located at the apical side of the epithelial layer and protect it from the inhaled antigen cells 
by phagocytosis. Dendritic cells will capture antigens, process and present antigen peptide to naive T cells, and 
trigger their differentiation into antigen-specific effector T cells.
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populations and the advancements made in prepar-
ing sophisticated NP systems, we propose that there 
is plenty of room for the development of novel pulmo-
nary drug delivery approaches for the treatment and 
diagnosis of pulmonary disorders.
General principles of NP systems for medical 
applications
Intense research efforts have been focused on the 
development of NPs for novel biomedical applications. 
However, prior to considering complex in vivo studies 
or clinical trials with such nanocarriers, a comprehen-
sive in-depth knowledge of NP–cell interactions on the 
single-cell level is required. For this, an exact control 
and thorough characterization of both the materials 
and the cell-model systems must be employed.
Regarding the synthesis and characterization of 
medically relevant NPs, research has mainly been 
focused on revealing any physicochemical related cell 
responses as well as on the potential adverse effects of 
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Figure 2. Antigen processing and presentation by dendritic cells to the naive T cells. Upon the antigen (or the nanoparticle-antigen 
complex) uptake, the antigen-derived peptide may be presented to the naive T cells via the major histocompatibility complex (MHC II) 
in combination with co-stimulatory molecules (CD40, CD80, CD86) and cytokines, released by T-helper cells. The activated T cells 
differentiate into different subsets of effector T cells (Th1, Th2, Treg and Th17).  
CD80/86/28/40/54: Clusters of differentiation, i.e., proteins involved as a co-stimulatory signals in T-cell activation; MHC II: Major 
histocompatibility complex class II molecules are heterodimeric proteins expressed in antigen presenting cells and involved in the i.e., 
MHC class II-dependent pathway of antigen presentation (phagocyted compounds); Th1, Th2, Treg and Th17: Different subsets of 
T-helper cells, which are responsible for production of cytokines, involved in activation of T cells (among other processes).
Nanoparticle Antigen
Antigen-derived peptideNanoparticle + antigen
CD80
CD86
CD4
MHC II
Antigen
uptake
Antigen
processing
Antigen
presentation
Naive CD4+ T cells differentiate
into multiple effector subsets
future science group
Review    Fytianos, Drasler, Blank et al.
those NPs in biological systems [33]. Both for basic and 
applied scientific research it is particularly important to 
address the fundamental question regarding the state 
of the material in a complex biological environment, 
such as cell culture media containing, for example, 
proteins, lipids or electrolytes, which might essentially 
alter the physicochemical properties of the NPs [34,35] 
and consequently impact their cellular interaction 
in vitro and in vivo. Moreover, the interactions of NPs 
with cells depends also on their physicochemical prop-
erties, such as size, shape and surface charge [36,37]. In 
addition, due to the high complexity of the cellular sys-
tems, each individual cell type might react differently 
to another when encountering the same NPs [25].
An example of NPs with potential biomedical appli-
cations are gold NPs, which are chemically stable, have 
high electron density and possess high affinity toward 
biomolecules, such as amino acids, proteins and 
DNA, rendering those particles suitable candidates 
for drug carriers and imaging reagents [38]. Promising 
in vitro results have been obtained with conjugated 
gold NPs in cancer research for detection and treat-
ment of tumor cells in vitro [39,40]. Moreover, diverse 
biodegradable and biocompatible polymer-based NPs, 
such as polylactic-co-glycolic acid (PLGA), have been 
shown to improve vaccination efficiency and provide 
heightened potency, thus present promising antigen 
delivery vehicles for diverse vaccine applications [41–43]. 
Another example of promising biomedical NPs are the 
super-paramagnetic iron oxide NPs (SPIONs) which 
have routinely been utilized as contrast agents in mag-
netic resonance imaging, in particular for transverse 
(or spin–spin) relaxation time (T2) imaging [44].
Inhalative nanocarriers: state-of-the-art
General knowledge about immune responses upon 
exposure to NPs (i.e., immunostimulation and immu-
nosuppression) is very limited, particularly with respect 
to lung-resident immune cells. Since upon inhalation 
NPs can be recognized by the organism as foreign 
materials, surface modification of NPs is essentially 
required in order to avoid or minimize any potential 
undesired pathological conditions (i.e., cell activation 
and hypersensitivity).
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There has been a growing interest in the field of NP-
based drug delivery research in the respiratory system, 
which is presented in Table 1. Various types of nano-
materials (i.e., lipid-based, polymers, metals coated 
with polymer, antibody-conjugated, carbon) have been 
used as agents in various pulmonary vaccines, where 
the DCs are predominantly the main target, as well 
as for targeting alveolar macrophages, since pathogens 
such as bacteria or fungi utilize them as a breeding 
ground (for a review see [45]).
In order to fully understand the interactions between 
NPs and lung-resident immune cells, careful design 
thorough characterization and proper control of all the 
synthetic steps is essential in the manufacture of NPs 
suitable for biomedical applications [56]. In addition to 
that, the potential effects of NPs on the cells must be 
evaluated, which requires a detailed cellular character-
ization; for this reason, well-studied in vitro model sys-
tems have to be applied in order to achieve realistic and 
accurate data [57].
The human lung immune system
The immune system is intended to protect the organ-
ism from possibly harmful materials that are recognized 
as foreign substances (antigens) [58]. First, the innate 
immune system is characterized as the organism’s ‘first 
line of defense’ and it thus provides rapid sensing and 
elimination of pathogens. It consists of the physical 
barriers (epithelial, mucus and surfactant layers) which 
cover the respiratory tract as well as the cytokines 
(which modulate cellular functions) and the mem-
brane receptors (to which the antigens can bind), which 
are both primarily considered as parts of the innate 
immune system [59]. Second, the adaptive immune sys-
tem provides an antigen-specific defense, and is respon-
sible for generation of the immunological memory. Its 
Table 1. A brief summary of various types of nanocarrier-based methods that have been investigated for inhalation-
oriented drug and vaccine delivery in the lungs.
NPs type Cell targeted Immunological function Study (year) Ref.
Lipid and polymer NPs APCs of the lymphoid system – Enhancement of antigen 
   immunoavailability 
– Antigen signal recognition 
– Immunomodulation
Csaba et al. (2009) [47]
PEGylated dendrimers Lung tissue/blood Specific site/drug delivery Ryan et al. (2013) [48]
PLGA Diphtheria infected cells in 
the upper lung compartment
Enhanced IgA production Muttil et al. (2010) [49]
PLA and PLGA Cell targeting via Hepatitis B 
antigen antibody
Enhancement of immune 
responses
Thomas et al. (2010) [50]
Silica NPs Lung tumor cells Anticancer Taratula et al. (2011) [51]
Mannose-functionalized 
polymer NPs
Bone marrow mouse DCs Immune stimulation Carrillo-Conde et al. 
(2011)
[52]
Polypropylene sulfide NPs CD4+ T cells Enhanced antigen presentation Stano et al. (2012) [53]
Lipid nanocarriers 
conjugated with drugs and 
nucleic acids
Lung tumor cells Enhanced antitumor activity Taratula et al. (2013) [51]
Gold cores coated with 
galactofuranose conjugated 
with anti-DC-SIGN antibodies
Human blood monocyte 
derived dendritic cells
– Activation, maturation 
– Release of IL-6 and TNF-α
Chiodo et al. (2014) [54]
Polystyrene particles Mouse, respiratory tract 
dendritic cells
– Enhanced uptake of smaller 
   NPs
Blank et al. (2013) [25]
  – Enhanced activation of 
   antigen (OVA) specific T cells
Seydoux et al. (2014) [55]
  – Reduced inflammatory 
   symptoms when applied prior 
   to sensitization and challenge
Hardy et al. (2012) [19]
APC: Antigen-presenting cell; DC: Dendritic cell; NP: Nanoparticle; PEGylated: Covalently or noncovalently attached or amalgamated polyethylene glycol (PEG) 
polymer chains; PLA: Polylactic acid; PLGA: Poly(lactic-co-glycolic acid). 
Adapted with permission from [46].
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main feature is a tightly regulated interplay between 
the antigen presenting cells, such as macrophages or 
DCs, and the main actors of the adaptive immunity, 
T and B lymphocytes; the latter are responsible for the 
antigen-specific receptor-mediated antibody produc-
tion. Generally, the adaptive immune system acts after 
the innate immune response when B and T-cell recep-
tors become specific for the antigen after their first 
encounter and start to clonally expand. A proportion 
of these cells may persist as memory B or T cells, and 
in the case of re-exposure to the same pathogen, these 
receptors provide a capability of rapid response (based 
on the principle of the immunological memory) [60].
Upon entering the respiratory tract, the fate of 
deposited NPs not only depends on their physicochem-
ical properties (e.g., particle size) [61] but also on the 
exposed cell type, that is, phagocytes (macrophages), 
antigen-presenting cells and epithelial or endothelial 
cells. Inhaled particles in the airways may trigger an 
early response of the innate immune system (epithe-
lium, surfactant proteins, phagocytes such as neutro-
phils and macrophages, natural killer cells, mast cells, 
eosinophils, basophils and innate lymphoid cells), 
followed by a downstream response of the adaptive 
immune system’s secretion of antibodies and T-cell 
responses) [46].
Cells of the lung immune system & selected 
cell models
An overview of the important structural organi-
zation of the lung immune system is presented in 
Figures 1 & 2. The theory behind the basic principles of 
immunology is beyond the scope of this review, but has 
been elegantly presented elsewhere [59,60]. However, a 
brief introduction of the individual components of the 
immune system in lungs is given below.
Macrophages
Macrophages are professional phagocyte cells of the 
immune system (i.e., innate immunity) and their main 
function is to engulf antigens. They are involved in 
wound healing (i.e., tissue repair) and immune regu-
lation (i.e., cell signaling and cytokine secretion) [62]. 
Airway as well as alveolar macrophages is located at the 
apical side of the epithelial layer in the air–blood inter-
face and protect it from inhaled antigens (i.e., toxic and 
allergic particles) by macrophage-mediated  clearance 
(i.e., phagocytosis) [63].
For the purpose of in vitro experiments to test their 
interaction with NPs, monocytes can be isolated from 
human buffy coat and differentiated into mature 
macro phages (monocyte-derived macrophages) with 
the addition of monocyte colony stimulating fac-
tor [64]; production of such primary cells can be very 
reproducible and represent a reliable in vitro system. 
Regarding the cell lines, the most commonly used are 
J774.1a (mouse macrophages derived from ascites) 
and THP-1 (human peripheral blood derived from 
 monocytic  leukemia patients).
DCs
DCs are a very important immune cell type as they 
present antigens (i.e., antigen-presenting cells [APCs]) 
to the T cells. For this reason, they have been described 
as the ‘bridge’ between the innate (antigen uptake) 
and the adaptive (antigen presentation) immune sys-
tem. Their main function is to take up antigens, to 
process them (by proteolytic cleavage) and to present 
the fragments to the T cells via receptor-mediated 
mechanisms; the latter occurs via the MHC II recep-
tor, a receptor widely present on the surface of human 
DCs, in combination with co-stimulatory molecules 
and cytokines [65].
Regarding in vitro experiments, isolation of mono-
cytes from human buffy coat is common practice, as 
well as their differentiation into mature DCs (mono-
cyte derived dendritic cells: MDDCs), with the addi-
tion of growth factors such as granulocyte-monocyte 
colony stimulating factor and IL-4 [66].
T cells
T cells play a key role in adaptive immunity, since they 
communicate with DCs; activated DCs present the 
antigen fragment on the MHC-II receptor which pos-
sesses high affinity for the T-cell receptor. T cells can be 
subdivided into two major types: helper T cells (CD4+; 
modulation of the immune responses) and cytotoxic 
T cells (CD8+; destroying bacterial infected, cancer 
and apoptotic cells) [67,68]. Upon interacting with DCs, 
T cells are activated and they differentiate toward dif-
ferent fates, depending on the signal obtained from the 
DCs (antigenic specificity) [69].
For in vitro studies, T cells can be generated from 
human buffy coat from the CD14-negative fraction 
(CD14-) and purified, with the CD4 positive fraction 
(CD4+) being used for generation of human T cells 
in vitro [70]. The most common approach for measur-
ing T-cell activation and proliferation in vitro is via 
radiolabeled compounds (such as thymidine, which is 
integrated into the DNA upon replication of the cells), 
as described by Blank et al. in 2011 [70].
B cells
Briefly, B cells represent the second class of lympho-
cytes involved in the adaptive immune system and are 
mainly associated with antibody-based responses [67]. 
Mature naive B cells mainly circulate through lym-
phoid organs in the periphery until they are activated 
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by an encounter with their cognate antigen, inducing 
production and secretion of antibodies specific for 
individual antigens.
Similar to T cells, isolation of B cells can be per-
formed via magnetic separation from human buffy 
coat in vitro (characterized by expression of surface 
markers CD19/CD20). The lineage of human B cells 
and their role in immunity in the respiratory system 
has recently been reviewed and described in detail [71].
NP interactions with lung immune cells 
in vitro
Generally, the interaction of NPs with immune cells is 
determined by the physicochemical properties of the 
NPs, predominantly by their surface coatings (reviewed 
recently [28,31]). At present, there is a lack of data on 
the immune responses to nanosized particles coming 
into contact with the respiratory system. Not only cell 
viability, cytotoxicity and cytokine secretion but also 
phenotypic and activation marker expression, as well 
as antigen uptake and processing capacities, need to be 
examined and considered in order to fully understand 
the effect of NPs on immune cells. Undoubtedly, data 
on their immune-stimulatory or immune-suppressive 
effects will determine the fate of novel therapeutic and 
diagnostic NP-based approaches [19,24,29,31,70].
Monoculture cell studies
Macrophages
In general, macrophages readily take up NPs, there-
fore they are frequently the cells of interest in various 
diagnostic and therapeutic studies, for example, in the 
metal NP-based imaging and targeting of cells asso-
ciated with various human diseases [24,72–74]. To date, 
various micro- or nano-sized systems have been devised 
as promising drug vehicles targeting pulmonary mac-
rophages via specific surface receptor recognition-based 
direction or passively (based on the high phagocyto-
sis activity of macrophages) [45,75]. Regarding specific 
macrophage targeting, the most extensively studied are 
the various biodegradable polymer-based NPs. It has 
been suggested that inflammatory responses depend 
on uptake (internalization) pathways, as demonstrated 
on an example of PLGA NPs, which elicit lower 
inflammatory cytokine production in murine macro-
phages J774 compared with  microparticles of the same 
composition [76].
In addition, other types of NPs, such as lipid-latex-
based NPs, have been proposed as promising platforms 
for specific imaging of proinflammatory macrophages 
in various lung disease diagnostics [75]. Also, single-
walled carbon nanotubes were reported to be biode-
gradable by the action of the THP-1 human monocytic 
cell line [77].
DCs
DCs are frequently applied as novel nanovaccine 
approaches in experimental immunotherapy studies for 
the treatment of cancer and infectious diseases [78,79]. 
Similar to macrophages, polymer-based nanocarri-
ers, such PLGA NPs, have been proposed as suitable 
for the targeting of DCs and subsequent activation of 
T cells [41–43]. The outcomes of our previous study sug-
gested that MDDCs exposed to poly(vinyl alcohol)-
coated SPIONs caused downregulation of antigen pro-
cessing and CD4+ T-cell stimulation, thus reverting 
the DCs to a more functionally immature state [70]. 
It has been reported that NP shape, size and surface 
charge have a significant impact on DCs; in particu-
lar, a higher phagocytic activity has been reported for 
positively charged particles. With respect to this, our 
group has recently demonstrated that NP surface mod-
ifications can significantly modulate uptake by human 
monocyte-derived DCs, however, it is difficult to relate 
this to cellular responses [80].
B & T lymphocytes
There are few studies on the interaction of NPs with 
T and B cells, and an even smaller number of stud-
ies reporting NP-influenced antibody production by 
B cells. There have been some reports on the activation 
of naive B cells by antigen-loaded calcium-phosphate-
based NPs [81], as well as on the impact of engineered 
NPs on cell activation and subsequent induction of 
antibody production by B cells (reviewed in [31]). Gold 
NPs were found to induce activation of mouse spleen-
derived B cells and promote immunoglobulin G secre-
tion in vitro, ex vivo and in vivo [82], whereas a single 
exposure to iron oxide NPs attenuated antigen-specific 
antibody production [83]. It has been shown that gold 
NPs can influence T-cell proliferation both in vitro and 
in vivo [82]. On the other hand, a recent study showed 
that gold NPs did not affect T-cell function and pro-
liferation, suggesting gold NP labeled T cells can be 
used in NP-coupled immunotherapy, for example, for 
trafficking lung-resident cancer cells [84]. However, any 
further impact of NPs on B-lymphocyte function, such 
as the induction and/or inhibition of antibody produc-
tion, remains unclear [31,72]. It has also been reported 
that gold NPs themselves do not cause T-cell prolif-
eration, but simultaneous exposure to gold NPs and 
antigens can have a synergistic effect in terms of T-cell 
proliferation [85]. Moreover, polymer-based nanocar-
rier systems were shown to deliver antigens to DCs, 
resulting in an increased cytokine production and thus 
enhanced CD8+ T-cell priming, which suggests that 
oxidation-sensitive polymersomes can function as a 
vaccine delivery platform for inducing cell-mediated 
antigen-specific immune responses [86].
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Figure 3. (A) Schematic drawing of the triple-cell co-culture model composed of epithelial cells, monocyte-derived 
macrophages and dendritic cells. The cells are exposed to air in the upper chamber and to cell culture medium in 
the lower part. (B) Laser scanning images of the model. Epithelial cells (white, volume rendering), macrophages 
(red, surface rendering), and dendritic cells (light blue, surface rendering) are shown. The same data set is shown 
from above (upper image) and from below (lower image). 
Adapted with permission from [90].  
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3D lung cell model studies
Since inhalation is widely accepted as the primary route 
of entry for aerosolized NPs into the human body [4], 
accurate and realistic studies need to be performed in 
order to examine the effects of inhaled NPs on lung 
cells [87–89]. Advanced in vitro co-culture models are 
becoming increasingly promising, since they provide 
a more ethical, cost–effective and faster alternative to 
in vivo models.
Overall, 3D co-culture models exposed to air-liquid 
interface conditions are very well characterized mod-
els that provide accurate data, by virtue of them being 
very similar to the in vivo setting (Figure 3; [90]). Com-
plementary to this, 3D co-cultures can be aerosolized 
with NP suspensions, after which numerous endpoints 
such as cellular uptake, functional and immunologi-
cal properties can be measured [88,89,91,92]. Apart from 
the need for good cellular models, sophisticated instru-
ments that can deliver NP aerosols in a dose-controlled 
manner are also mandatory, for instance the air–liq-
uid interface cell exposure system or the commercially 
available Vitrocell® Cloud.
In vitro & in vivo settings
In some recent in vitro monoculture studies on DCs, 
the absence of an immunological effect was observed 
with gold and iron oxide NPs [70,80,93] at concentrations 
up to 20 μg/ml, whereas there is evidence that certain 
NP types at higher concentrations can result in altera-
tions of the antigen uptake and processing capacities, 
which could result in T-cell proliferation [53,70,85]. 
However, it is difficult to correlate cellular uptake with 
biological endpoints because different NP types can 
elicit different biological responses [56,80].
Both in vitro and in vivo studies report that the size 
and surface of an NP play the most important roles in 
its immunomodulatory effect [94]. For example, 20-nm 
polystyrene NPs were found to enhance T-cell prolifera-
tion in lung-draining lymph nodes of mice, while 1000 
nm polystyrene NPs failed to induce T-cell prolifera-
tion [25]. In addition, 7 nm gold NPs were detected in the 
blood of the experimental mice at higher  concentrations 
than when 20 nm gold NPs were used [61].
From an in vivo and organ translocation/biodistri-
bution perspective, Kreyling and colleagues observed 
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higher amounts of positively charged gold NPs in the 
lungs after 24 h of intratracheal instillation when com-
pared with the use of their negatively charged counter-
parts [16,61]. The surface charge of gold NPs can influ-
ence translocation in vivo, with –COO–-functionalized 
gold NPs having a significantly higher translocation rate 
than the –NH
3
+-functionalized gold NPs. This effec-
tively means that the blood circulation is higher for the 
–COO–-functionalized particles, whereas the –NH
3
+-
functionalized particles are retained in the organs [16]. 
Similarly, alveolar macrophages and different subpopu-
lations of pulmonary DCs preferentially captured posi-
tively charged gold NPs compared with their negatively 
charged counterparts in mice in vivo, and also induced 
enhanced OVA-specific CD4+ T-cell stimulation [95]. 
However, the dose reaching the targeted cells also needs 
to be considered; for instance, SPIONs, administered via 
inhalation pathways, were found to induce dose-related 
expression of some similar inflammatory markers in 
murine macrophages both in vitro and in vivo, whereas 
discrepancies were observed for nonimmunological, 
respiratory epithelial cells [96]. Nevertheless, the aspect 
of the biocorona on NPs has to be deciphered in the 
 assessment of NP delivery to the respiratory system [97].
It is important to mention that immunizing ani-
mals with specific NPs, even in the presence of strong 
adjuvants, is frequently reported to be unsuccessful in 
terms of generating NP-specific antibodies, however, it 
can be successfully induced by conjugation of NPs to a 
protein carrier (discussed in [31]).
Nevertheless, it should be noted that NP-based 
vaccines combined with adjuvants can elicit a strong 
cellular immune response upon viral infections, for 
example, activation of T-cell priming. However, can-
cer-based vaccines also aim to activate CD8+ T cells. 
In this respect, biodegradable NPs are considered an 
attractive delivery system since they can deliver high 
yields of peptides and drugs along with adjuvants to the 
site of interest, and thus achieve an effective immune 
response [98].
Future perspective
Currently, extensive research is being devoted to the 
design of novel nanotechnology-based approaches for 
the inhalation-based treatment of a range of pulmonary 
diseases, particularly for targeting lung-resident immune 
cells. Although many drugs are already available on the 
market to treat pulmonary disorders and various novel 
nanocarrier types have been proposed, more investiga-
tion is needed: especially regarding the specific targeting 
of single immune cell types in human lungs. Indeed, 
biomedicine can significantly benefit from the use of 
nanotechnology-based carriers, yet proper risk assess-
ment of such novel materials will require thorough char-
acterization of their immunomodulatory effects, either 
desired or  unintentional.
Most of the present studies are performed using in vitro 
approaches (using either human or murine derived cells), 
or in vivo studies on rodents. Due to the general desire 
to reduce animal experiments, and the ethical ques-
tions regarding human in vivo studies, the application of 
sophisticated in vitro approaches using relevant immune 
and lung epithelial cells will present an increasingly 
important step in the evaluation of biomedical NPs.
From an immunotoxicology perspective, it is of 
critical importance to understand if an organism rec-
ognizes NPs as foreign material (antigen), thereby trig-
gering innate immune responses [97]. Despite the scien-
tific advances made over the last decade in the area of 
NP-immune system interactions, the development of 
nanocarrier vaccines that can result in strong cellular 
immune responses will be key for the improvement of 
clinical outcomes.
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Executive summary
•	 Combination of the anatomical features of the human respiratory tract with the unique physicochemical 
properties of nanoparticles (NPs) can serve as an adequate basis for the development of novel inhalative NP-
based approaches for the treatment of various lung diseases.
•	 NP-based drug delivery is a rapidly emerging research field requiring a highly interdisciplinary approach by 
groups of experts encompassing material scientists, physicists, biologists as well as clinicians, in order to meet 
the requirements for (bio)medical applications.
•	 Well-defined and characterized in vitro model systems of single immune cells – but also more complex 3D 
lung models involving immune cells – represent suitable approaches for the assessment of NP-immune system 
interactions and thus contribute to the development of the ‘nanoimmuno’-based therapeutic approaches.
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